Nitric oxide (NO) and cyclooxygenase-2 (COX-2) cross-talk in co-cultures of tumor spheroids with normal cells

Cancer Microenvironment

Volumn 4, Issue 2, 2011, Pages 187-198

  Paduch, Roman ^a   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Co cultures; Colon carcinoma; Cyclooxygenase 2; Nitric oxide

Indexed keywords

CYCLOOXYGENASE 2; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2;

ARTICLE; CANCER GRADING; CELL MIGRATION; CELL MOTILITY; COCULTURE; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR SPHEROID;

EID: 81855185297     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0063-x     Document Type: Article

References (48)

1. Rao ChV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62:165-170 (Pubitemid 34074001)
2. Tanaka T, Kohno H, Shimada R, Kagami S, Yamaguchi F, Kataoka S, Ariga T, Murakami A, Koshimizu K, Ohigashi H (2000) Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 21:1183-1189 (Pubitemid 30389345)
3. Rao ChV, Kawamori T, Hamid R, Reddy BS (1999) Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 20:641-644 (Pubitemid 29151301)
4. Lala PK, Chakraborty Ch (2001) Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 3:149-156 (Pubitemid 33585926)
5. Conners W, Whitebeck C, Chicester P, Legget R, Lin AD-Y, Johnson A, Kogan B, Levin R, Mannikarottu A (2006) L-NAME, a nitric oxide inhibitor, diminishes oxidative damage in urinary bladder partial outlet obstruction. Am J Physiol-Renal Physiol 290:F357-F363 (Pubitemid 43724990)
6. Rao ChV (2004) Nitric oxide signalling in colon cancer chemoprevention. Mutat Res 555:107-119
7. Shang Z-J, Li Z-B (2006) In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. Int J Oral Maxillofac Surg 35:539-543
8. Gavilanes J, Moro MA, Lizasoain I, Lorenzo P, Pérez A, Leza JC, Alvarez-Vicent JJ (1999) Nitric oxide synthase activity in human squamous cell carcinoma of the head and neck. Laryngoscope 109:148-152 (Pubitemid 29035608)
9. Yu L-B, Dong X-S, Sun W-Z, Zhao D-L, Yang Y (2005) Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11:6385-6388 (Pubitemid 43014009)
10. Park S-W, Lee S-G, Song S-H, Heo D-S, Park B-J, Lee D-W, Kim K-H, Sung M-W (2003) The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int J Cancer 107:729-738 (Pubitemid 37339726)
11. Zhang H, Sun X-F (2002) Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97:1037-1041 (Pubitemid 34408266)
12. Giercksky K-E (2001) COX-2 inhibition and prevention of cancer. Best Prac Res: Clin Gastroenterol 15:821-833 (Pubitemid 32982368)
13. Yoshimatsu K, Yamaguchi K, Otani T, Aizawa M, Ogawa K (2007) Cyclooxygenase II: a molecular target for colorectal cancer prevention and treatment? Ann Cancer Res Therap 15:14-21
14. Huang DS, Shen K-Z, Wei J-F, Liang T-B, Zheng SS, Xie H-Y (2005) Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. World J Gastroenterol 11:204-207 (Pubitemid 40125204)
15. Larkins TL, Nowell M, Singh S, Sanford GL (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6: art. No. 181
16. Tammali R, Ramana KV, Srivastava SK (2007) Aldose reductase regulates TNF-a-induced PGE2 production in human colon cancer cells. Cancer Lett 252:299-306 (Pubitemid 46823949)
17. Wendum D, Masliah J, Trugnan G, Fléjou J-F (2004) Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445:327-333 (Pubitemid 39517756)
18. Paduch R, Walter-Croneck A, Zdzisinska B, Szuster-Ciesielska A, Kandefer-Szerszen M (2005) Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer. Cell Biol Int 29:497-505 (Pubitemid 41138211)
19. Buecher B, Broquet A, Bouancheau D, Heymann M-F, Jarry A, Denis MG, Bonnet C, Galmiche J-P, Blottière HM (2003) Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. Dig Liver Dis 35:557-565 (Pubitemid 41070412)
20. Bijman MNA, Hermelink CA, van Berkel MPA, Laan AC, Janmaat ML, Peters GJ, Boven E (2008) Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol 75:427-437 (Pubitemid 350298473)
21. Tuynman JB, Peppelenbosch MP, Richel DJ (2004) COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 52:81-101 (Pubitemid 39410538)
22. Peek Jr RM (2004) Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol 54(Suppl. 1):S50-S56 (Pubitemid 39517749)
23. Hasegawa K, Ichikawa W, Fujita T, Ohno R, Okusa T, Yoshinaga K, Sugihara K (2001) Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37:1469-1474 (Pubitemid 32744675)
24. Dempke W, Rie Ch, Grothey A, Schmoll H-J (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer Res Clin Oncol 127:411-417 (Pubitemid 32524357)
25. Sun Q, Liu Q, Zheng Y, Cao X (2008) Rapamycin suppresses TLR-4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-β B activation. Mol Immunol 45:2929-2936
26. Morioka Y, Ikeda M, Saiga A, Fujii N, Ishimoto Y, Arita H, Hanasaki K (2000) Potential role of group X secretory phospholipase A2 in cyclooxygenase-2-dependent PGE2 formation during colon tumorigenesis. FEBS Lett 487:262-266 (Pubitemid 32057123)
27. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterol 111:1134-1140 (Pubitemid 26327618)
28. Hsi LC, Baek SJ, Eling TE (2000) Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 256:563-570 (Pubitemid 30244214)
29. Talmadge JE (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13:5243-5248 (Pubitemid 47510346)
30. Namkoong S, Kim Y-M (2010) Therapeutic application of nitric oxide in human diseases. Biomol Ther 18:351-362
31. Oshikawa T, Okamoto M, Tano T, Ahmed SU, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Sato M (2006) Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent. Int Immunopharmacol 6:764-773
32. Ma Q, Hoper M, Anderson N, Rowlands BJ (1996) Effect of supplemental L-arginine in a chemical-induced model of colorectal cancer. World J Surg 20:1087-1091 (Pubitemid 26322101)
33. Ma Q, Wang Y, Gao X, Ma Z, Song Z (2007) L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res 13:7407-7412
34. Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, Abramson SB (2000) Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol 165:1582-1587 (Pubitemid 30604595)
35. Ghosh DK, Misukonis MA, Reich Ch, Pisetsky DS, Weinberg JB (2001) Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. Infect Immun 69:7703-7710 (Pubitemid 33086600)
36. Cianchi F, Cortesini C, Fantappiè O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E (2004) Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10:2694-2704 (Pubitemid 38509144)
37. Guastadisegni C, Nicolini A, Balduzzi M, Ajmone-Cat MA, Minghetti L (2002) Modulation of PGE2 and TNFα by nitric oxide in resting and LPS-activated RAW 264.7 cells. Cytokine 19:175-180
38. Motta AB, Gonzales ET, Rudolph I, Gimeno MF (1999) Regulation of prostaglandin production by nitric oxide in rat smooth muscle myometrial cells. Prostaglandins Leukot Essent Fatty Acids 60:73-76 (Pubitemid 29182168)
39. Novaro V, Rettori V, Gonzáles ET, Jawerbaum A, Faletti A, Canteros G, de Gimeno MAF (1996) Interaction between uterine PGE and PGF2α production and the nitridergic system during embryonic implantation in the rat. Prostaglandins 51:363-376 (Pubitemid 26279749)
40. Ohno R, Miyazawa T, Hayashi Y, Kanatsu K, Tanaka A, Takeuchi K (2002) Induction of intestinal damage by rofecoxib, the selective COX-2 inhibitor, under inhibition of nitric oxide production in rats. Immunopharmacology 10:435-447 (Pubitemid 36637462)
41. ω -nitro-L-arginine methyl ester and indomethacin reduces the elevation of brain PGE2 content and prevents seizures and hippocampal damage evoked by LiCl and tacrine in rat. Exp Neurol 149:349-355 (Pubitemid 28115073)
42. Yu L-B, Dong X-S, Sun W-Z, Zhao D-L, Yang Y (2005) Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11:6385-6388 (Pubitemid 43014009)
43. West SD, Suliburk JW, Helmer KS, Mercer DW (2008) Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase. Crit Care Med 36:572-579 (Pubitemid 351158635)
44. Payá M, Pastor PG, Coloma J, Alcaraz MJ (1997) Nitric oxide synthase and cyclo-oxygenase pathways in the inflammatory response induced by zymosan in the rat air pouch. Br J Pharmacol 120:1445-1452 (Pubitemid 27192434)
45. Nishikawa M, Stapleton P, Freeman TA, Gaughan JP, Matsuda T, Daly JM (2004) NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg 199:428-435 (Pubitemid 39120058)
46. Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP, Saed GM (2003) Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 88:429-433 (Pubitemid 36332001)
47. Park S-W, Sung M-W, Heo D-S, Inoue H, Shim S-H, Kim K-H (2005) Nitric oxide upregulates the cyclooxygenase-2 expression through the camp-response element in its promoter in several cancer cell lines. Oncogene 24:6689-6698 (Pubitemid 41486799)
48. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D (2005) Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57:217-252 (Pubitemid 41043885)